Literature DB >> 28831520

Does the evidence support population-wide screening for type 2 diabetes? No.

Jonathan E Shaw1.   

Abstract

Large-scale, centrally-coordinated screening for undiagnosed type 2 diabetes is an attractive option to reduce the mortality and morbidity resulting from inadequately controlled diabetes. However, there is limited research examining the direct consequences of such screening programmes on outcomes such as cardiovascular disease and death. Two papers published in this edition of Diabetologia (DOIs: 10.1007/s00125-017-4323-2 and 10.1007/s00125-017-4299-y ) examine data from one of the very few trials conducted in this area. Overall, there was little benefit that could be directly related to the screening programme. In part, this was due to the high levels of opportunistic screening in the control group. Thus, when there are high levels of opportunistic screening for type 2 diabetes, there remains no clear evidence of benefit of centrally-coordinated screening programmes that approach individuals outside usual healthcare settings.

Entities:  

Keywords:  Cardiovascular disease; Mortality; Screening; Type 2 diabetes

Mesh:

Year:  2017        PMID: 28831520     DOI: 10.1007/s00125-017-4393-1

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  14 in total

1.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

2.  The performance of diabetes risk prediction models in new populations: the role of ethnicity of the development cohort.

Authors:  Stephanie K Tanamas; Dianna J Magliano; Beverley Balkau; Jaakko Tuomilehto; Sudhir Kowlessur; Stefan Söderberg; Paul Z Zimmet; Jonathan E Shaw
Journal:  Acta Diabetol       Date:  2014-07-05       Impact factor: 4.280

Review 3.  Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis.

Authors:  Connor A Emdin; Kazem Rahimi; Bruce Neal; Thomas Callender; Vlado Perkovic; Anushka Patel
Journal:  JAMA       Date:  2015-02-10       Impact factor: 56.272

4.  Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial.

Authors:  Simon J Griffin; Knut Borch-Johnsen; Melanie J Davies; Kamlesh Khunti; Guy E H M Rutten; Annelli Sandbæk; Stephen J Sharp; Rebecca K Simmons; Maureen van den Donk; Nicholas J Wareham; Torsten Lauritzen
Journal:  Lancet       Date:  2011-06-24       Impact factor: 79.321

Review 5.  Risk models and scores for type 2 diabetes: systematic review.

Authors:  Douglas Noble; Rohini Mathur; Tom Dent; Catherine Meads; Trisha Greenhalgh
Journal:  BMJ       Date:  2011-11-28

6.  Early Detection and Treatment of Type 2 Diabetes Reduce Cardiovascular Morbidity and Mortality: A Simulation of the Results of the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen-Detected Diabetes in Primary Care (ADDITION-Europe).

Authors:  William H Herman; Wen Ye; Simon J Griffin; Rebecca K Simmons; Melanie J Davies; Kamlesh Khunti; Guy E H M Rutten; Annelli Sandbaek; Torsten Lauritzen; Knut Borch-Johnsen; Morton B Brown; Nicholas J Wareham
Journal:  Diabetes Care       Date:  2015-05-18       Impact factor: 19.112

7.  Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults.

Authors:  Rebecca K Simmons; Simon J Griffin; Daniel R Witte; Knut Borch-Johnsen; Torsten Lauritzen; Annelli Sandbæk
Journal:  Diabetologia       Date:  2017-08-23       Impact factor: 10.122

8.  Screening for type 2 diabetes: do screen-detected cases fare better?

Authors:  Adina L Feldman; Simon J Griffin; Eva Fhärm; Margareta Norberg; Patrik Wennberg; Lars Weinehall; Olov Rolandsson
Journal:  Diabetologia       Date:  2017-08-23       Impact factor: 10.122

9.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.

Authors:  P M Kearney; L Blackwell; R Collins; A Keech; J Simes; R Peto; J Armitage; C Baigent
Journal:  Lancet       Date:  2008-01-12       Impact factor: 79.321

10.  Trends in laboratory testing for diabetes in Ontario, Canada 1995-2005: a population-based study.

Authors:  Sarah E Wilson; Lorraine L Lipscombe; Laura C Rosella; Douglas G Manuel
Journal:  BMC Health Serv Res       Date:  2009-02-27       Impact factor: 2.655

View more
  2 in total

1.  Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology.

Authors:  Bahira Shahim; Viveca Gyberg; Dirk De Bacquer; Kornelia Kotseva; Guy De Backer; Oliver Schnell; Jaakko Tuomilehto; David Wood; Lars Rydén
Journal:  Cardiovasc Diabetol       Date:  2018-01-24       Impact factor: 9.951

2.  All-cause mortality in adults with and without type 2 diabetes: findings from the national health monitoring in Germany.

Authors:  Susanne Röckl; Ralph Brinks; Jens Baumert; Rebecca Paprott; Yong Du; Christin Heidemann; Christa Scheidt-Nave
Journal:  BMJ Open Diabetes Res Care       Date:  2017-12-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.